Here is the snippet from the PR seel: Addition

Here is the snippet from the PR seel:

Additionally, Cellceutix has been approached by the Pioneer Valley Life Sciences Institute, a Baystate Medical Center/University of Massachusetts Amherst Research Partnership ("the Institute"), to collaborate on an innovative research project on Kevetrin™. The Institute wishes to investigate Kevetrin's antitumor activity related to risk factor aging and, as such, Cellceutix has initiated a major study in collaboration with the Institute.

Kevetrin™ has potent antitumor activity in several wild type and mutant p53 human tumor xenografts. It is well established that aging is a major risk factor for tumorigenesis. As mitochondrial function declines with age, it provides survival advantages to cancer cells. In mitochondrial respiration-deficient cells, p53 levels are reduced to undetectable levels. Since Kevetrin has been shown to be very effective in wild and mutant p53 tumors, it is highly desirable and important to understand Kevetrin's role in antitumor activity in the context of age-related mitochondrial dysfunction.

This study will provide vital insight and may have a considerable impact on the treatment of tumors associated with mitochondrial dysfunction due to aging. Dr. Nagendra Yadava, a leader in mitochondrial disease and aging, in the Department of Biology at University of Massachusetts Amherst, will initially head the research.